136 related articles for article (PubMed ID: 28629523)
1. Significance of Erythropoietin Receptor Antagonist EMP9 in Cancers.
Yasuda Y; Fujita M
Vitam Horm; 2017; 105():297-310. PubMed ID: 28629523
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin Receptor Antagonist Suppressed Ectopic Hemoglobin Synthesis in Xenografts of HeLa Cells to Promote Their Destruction.
Yasuda Y; Fujita M; Koike E; Obata K; Shiota M; Kotani Y; Musha T; Tsuji-Kawahara S; Satou T; Masuda S; Okano J; Yamasaki H; Okumoto K; Uesugi T; Nakao S; Hoshiai H; Mandai M
PLoS One; 2015; 10(4):e0122458. PubMed ID: 25874769
[TBL] [Abstract][Full Text] [Related]
3. No erythropoietin-induced growth is observed in non-small cell lung cancer cells.
Frille A; Leithner K; Olschewski A; Olschewski H; Wohlkönig C; Hrzenjak A
Int J Oncol; 2018 Feb; 52(2):518-526. PubMed ID: 29345289
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts.
Tankiewicz-Kwedlo A; Hermanowicz J; Surażynski A; Rożkiewicz D; Pryczynicz A; Domaniewski T; Pawlak K; Kemona A; Pawlak D
Mol Cell Biochem; 2016 Oct; 421(1-2):1-18. PubMed ID: 27543111
[TBL] [Abstract][Full Text] [Related]
5. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
[TBL] [Abstract][Full Text] [Related]
6. The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.
Wu P; Zhang N; Wang X; Zhang C; Li T; Ning X; Gong K
PLoS One; 2012; 7(9):e45122. PubMed ID: 23028796
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
[TBL] [Abstract][Full Text] [Related]
9. The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.
Hu W; Zhang Y; Jiang Z; Wang L; Li J; Chen S; Dai N; Si J
Tumour Biol; 2016 Aug; 37(8):11523-33. PubMed ID: 27086036
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.
Arcasoy MO; Karayal AF
Biochim Biophys Acta; 2005 Apr; 1740(1):17-28. PubMed ID: 15878737
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR
Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028
[TBL] [Abstract][Full Text] [Related]
13. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells.
Um M; Gross AW; Lodish HF
Cell Signal; 2007 Mar; 19(3):634-45. PubMed ID: 17045782
[TBL] [Abstract][Full Text] [Related]
14. Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.
Middleton SA; Barbone FP; Johnson DL; Thurmond RL; You Y; McMahon FJ; Jin R; Livnah O; Tullai J; Farrell FX; Goldsmith MA; Wilson IA; Jolliffe LK
J Biol Chem; 1999 May; 274(20):14163-9. PubMed ID: 10318834
[TBL] [Abstract][Full Text] [Related]
15. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation.
Livnah O; Johnson DL; Stura EA; Farrell FX; Barbone FP; You Y; Liu KD; Goldsmith MA; He W; Krause CD; Pestka S; Jolliffe LK; Wilson IA
Nat Struct Biol; 1998 Nov; 5(11):993-1004. PubMed ID: 9808045
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.
Larsson AM; Jirström K; Fredlund E; Nilsson S; Rydén L; Landberg G; Påhlman S
Clin Cancer Res; 2009 Sep; 15(17):5552-9. PubMed ID: 19706814
[TBL] [Abstract][Full Text] [Related]
17. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2.
Aguilar C; Aguilar C; Lopez-Marure R; Jiménez-Sánchez A; Rocha-Zavaleta L
Mol Med Rep; 2014 May; 9(5):1895-902. PubMed ID: 24626629
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin drives breast cancer progression by activation of its receptor EPOR.
Chan KK; Matchett KB; Coulter JA; Yuen HF; McCrudden CM; Zhang SD; Irwin GW; Davidson MA; Rülicke T; Schober S; Hengst L; Jaekel H; Platt-Higgins A; Rudland PS; Mills KI; Maxwell P; El-Tanani M; Lappin TR
Oncotarget; 2017 Jun; 8(24):38251-38263. PubMed ID: 28418910
[TBL] [Abstract][Full Text] [Related]
19. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation.
Hamadmad SN; Hohl RJ
Biochem Pharmacol; 2007 Aug; 74(4):590-600. PubMed ID: 17586475
[TBL] [Abstract][Full Text] [Related]
20. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells.
Jeong JY; Feldman L; Solar P; Szenajch J; Sytkowski AJ
Int J Cancer; 2008 Jan; 122(2):274-80. PubMed ID: 17893874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
